Copyright
©The Author(s) 2016.
World J Hematol. Feb 6, 2016; 5(1): 1-22
Published online Feb 6, 2016. doi: 10.5315/wjh.v5.i1.1
Published online Feb 6, 2016. doi: 10.5315/wjh.v5.i1.1
Gene(s) studied | Model/technique | Tractability to human MDS | Ref. | |||||||
Anemia | Multi-lineage cytopenias | Dysplasia | Bone marrow cellularity | HSPC skewing | Secondary leukemia | Latency to leukemia | Survival | |||
NUP98-HOXD13 | Transgenic | Yes | Yes | Yes | Hyper- | Yes | Yes2 | 14 mo | - | [69] |
Cd74-Nid67 | Large scale chromosomal deletion, RPS14 haploinsufficient | Yes | No | Yes | Hypo- | Yes | No | - | 1 | [92] |
SPARC | Knock-out | No | No | Yes | 1 | 1 | No | - | 1 | [97] |
MIR-145, MIR146a | Retroviral transduction | No | No | Yes | 1 | 1 | Yes | 4-14 mo | - | [143] |
APC | Transgenic, haploinsufficient | Yes | No | Yes | 1 | Yes | No | - | 3-8 mo | [99] |
Csnk1a1 | Transgenic, inducible | Yes | Yes | Yes | Yes | Yes | No | - | 1 | [94] |
Srsf2 | Transgenic, inducible | Yes | Yes | Yes | Normal | Yes | No | - | 1 | [98] |
U2af1 | Transgenic, inducible | No | No | No | Normal | Yes | No | - | - | [100] |
Sf3b1 | Transgenic, haploinsufficient | Yes | No | Yes | 1 | 1 | No | - | About 12 mo | [101] |
RUNX1-D171N | Retroviral transduction | Yes | Yes | Yes | Normal to hyper- | 1 | Yes | 4-13 mo | - | [105] |
RUNX1-S291fsX300 | Retroviral transduction | Yes | Yes | Yes | Normal to hyper- | 1 | Yes | 4-13 mo | - | [105] |
RUNX1S291fs/Ezh2 | Retroviral transduction | Yes | Yes | Yes | Variable | 1 | No | - | 262 d | [125] |
Tet2 | Transgenic, hypomorphic | Yes | Yes | Yes | Hyper- | Yes | No | - | 11 mo | [115] |
Tet2/Ezh2 | Transgenic, inducible | Yes | Yes | Yes | Hyper- | Yes | No | - | 10 mo | [141] |
ASXL1 | Transgenic, inducible | Yes | Yes | Yes | Hypo- | Yes | No | - | Median 50 wk | [122] |
Asxl1 | Transgenic, constitutive | Yes | Yes | Yes | Normal to hyper- | Yes3 | 16 mo | 8-42 d | - | [123] |
TERT | Transgenic, inducible | Yes | Yes | Yes | Hyper | Yes | Yes | 1 | 12 mo | [124] |
Evi1 | Retroviral transduction | Yes | Yes | Yes | Hyper- | 1 | No | - | 10-12 mo | [136] |
SALL4 | Transgenic | Yes | Yes | Yes | Hyper- | Yes | Yes | 6 wk to 12 mo | - | [139] |
Npm1 | Transgenic, haploinsufficient | No | No | Yes | Hyper | No | Yes | 24 mo | - | [138] |
NRASD12-BCL2 | Transgenic, inducible/constitutive | 1 | No | Yes | 1 | Yes | Yes | 3-6 mo | - | [142] |
Pten/Ship | Transgenic, Pten +/- Ship -/- | Yes | Yes | 1 | Hypo | Yes | No | - | 5 wk | [140] |
Dido | Knock-out | Yes | No | Yes | 1 | 1 | No | - | 1 | [137] |
Arid4a | Knock-out | Yes | Yes | Yes | Hyper- | 1 | Yes | 5 mo | - | [144] |
Mll5 | Knock-out | Yes | No | No | 1 | 1 | No | - | - | [145] |
- Citation: Tan SY, Smeets MF, Chalk AM, Nandurkar H, Walkley CR, Purton LE, Wall M. Insights into myelodysplastic syndromes from current preclinical models. World J Hematol 2016; 5(1): 1-22
- URL: https://www.wjgnet.com/2218-6204/full/v5/i1/1.htm
- DOI: https://dx.doi.org/10.5315/wjh.v5.i1.1